Home > Medical Reference > Encyclopedia (English)

Toggle: English / Spanish

Contenido Relacionado

Contenido en el Idioma Español de University of Maryland Medical Center

Cáncer de próstata - Prevention

Nombres alternativos

Cáncer de la próstata; Biopsia de próstata; Biopsia de la próstata; Puntaje de Gleason

Prevención:

El hecho de seguir una dieta vegetariana baja en grasas o una similar a la dieta japonesa tradicional puede reducir su riesgo. Esto incluiría alimentos ricos en ácidos grasos omega-3.

La finasterida (Proscar, genérica) y dutasterida (Avodart) son fármacos usados para tratar la hiperplasia prostática benigna (HPB).

La Sociedad Estadounidense de Oncología Clínica (ASCO) y la Asociación Urológica Estadounidense (AUA) recomiendan que los médicos analicen los pros y los contras de estos fármacos con hombres que:

Tengan un puntaje del PSA de 3.0 o por debajo
Los están examinando anualmente en busca de cáncer de próstata
Aún no muestran signos de cáncer de próstata

No todos los expertos están de acuerdo con esta recomendación.

Anatomía reproductiva masculina

Tracto urinario masculino

HPB

Cáncer de próstata

Examen de sangre PSA

Prostatectomía - Serie

Resección transuretral de la próstata (RTUP) - Serie

Reviewed last on: 9/23/2010
Scott Miller, MD, Urologist in private practice in Atlanta, Georgia. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

Referencias

Andriole GL, Crawford ED, Grubb RI 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.

Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180:1993-2004.

NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. V.2.2009. Accessed June 2009.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.

Walsh PC, DeWeese TL, et al. Clinical practice: localized prostate cancer. N Engl J Med. 2007;357(26):2696-2705.

Walsh PC. Chemoprevention of prostate cancer. N Engl J Med. 2010 Apr 1;362(13):1237-8.

Wilt TJ, MacDonald R, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435-448.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

Connect with UMMC

© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885